Your Global Leader in Stem Cell Market Research
Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).
The field of stem cell research has boomed over the past twelve months, bringing to light new ideas for treatments and applications. Here at BioInformant, we strive to do our best to provide you with the most up to date information related to the industry. As a supplement to our monthly round-ups, we thought it would be important to share the top ten most shared stem cell articles from the past year.
[Read more…]
While the cord blood banking industry emerged in the late 1980’s and early 1990’s, the cord tissue storage industry didn’t emerge until much later when a Taiwanese company launched the service in 2008 (Healthbank Biotech). By 2009, two companies in Hong Kong were offering the service of cord tissue storage. It took until 2010 for the first U.S. cord blood bank, Cord Blood Registry (CBR) to offer the service, which it started in July 2010.
Today, the majority of private U.S. cord blood banks offer the service. A more in-depth analysis of the rate of market penetration within the U.S. is provided below.
When an analysis of cord tissue storage was first completed by BioInformant in 2013, only nine companies where offering the service in the United States. These companies are shown in the table below. [Read more…]
Currently, there are a number of clinical trials that are investigating the therapeutic potential of mesenchymal stem cells derived from umbilical cord tissue, often called Wharton’s Jelly.
Specific conditions that have been or are now being researched for their potential to be treated with stem cells derived from cord tissue include:
Clinical trials currently listed as involving the use of cord-tissue derived mesenchymal stem cells include:
To search for more clinical trials using CT-MSCs, head to ClinicalTrials.gov and search for the following terms:
ClinicalTrials.gov is website maintained by the U.S. National Institutes of Health (NIH) that is a “registry and results database of publicly and privately supported clinical studies of human participants from around the world.” While an excellent resource, it does not include all clinical trials worldwide, including some which may be listed on international registries.
These searches will capture clinical trials that use varied vocabulary, as well as both singular and plural descriptions of the cell type. Other searches may be effective as well.
Mesenchymal stem cells (MSCs) can also be derived from other tissue sources besides the newborn umbilical cord.
Specifically, MSCs can be derived from adult sources that include adipose tissue, peripheral blood, and bone marrow, as well as from neonatal tissues that include parts of the placenta and umbilical cord, as explored in the image below. This is significant because pre-clinical and clinical advances with the use of MSCs derived from other sources than cord tissue will create a greater willingness to explore medical applications for cord tissue-derived MSCs.
IMAGE. SOURCES OF MESENCHYMAL STEM CELLS
BioInformant is the first and only market research firm to specialize in the stem cell industry. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been featured on news outlets including the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine.
This is an interview with Kyle Cetrulo, Founder and CEO of AuxoCell Laboratories, a company specializing in solid tissue processing using its AC:Px System. In addition to heading Auxocell and being a thought-leader on perinatal stem cells, Kyle is an organizer for the upcoming 2nd Annual Perinatal Stem Cell Society Conference that will take place March 2-4, 2016 in Aspen, CO.
[Read more…]
Recently released, the “Complete 2015-16 Global Cord Blood Banking Industry Report” explores new clinical trial market data supporting applications for hematopoietic stem cells (HSCs) from cord blood and mesenchymal stem cells (MSCs) from cord tissue. Within this rapidly evolving marketplace, those who choose to commit to understanding current opportunities and threats will be positioned for a substantial strategic advantage.
Because the global cord blood banking industry has matured substantially over the past few years, new market forces have created both serious threats and novel opportunities. [Read more…]
